nab-paclitaxel/carboplatin (nab-P/C) induction therapy in squamous (SCC) non-small cell lung cancer (NSCLC): Interim safety results from ABOUND.sqm

被引：0
|
作者：
Gridelli, C. [1 ]
McCleod, M. [2 ]
Morgensztern, D. [3 ]
Daniel, D. B. [4 ]
Page, R. [5 ]
Wehler, T. [6 ]
Juan, O. [7 ]
Levy, B. [8 ]
Ardizzoni, A. [9 ]
Berry, T. [10 ]
Chen, T. [10 ]
Trunova, N. [10 ]
Jotte, R. [11 ]
机构：
[1] SG Moscati Hosp, Oncol, Avellino, Italy
[2] Florida Canc Specialists, Oncol, Cape Coral, FL USA
[3] Washington Univ, Schoo Med, Oncol, St Louis, MO USA
[4] Tennessee Oncol, Oncol, Chattanooga, TN USA
[5] Ctr Canc & Blood Disorders, Oncol, Ft Worth, TX USA
[6] Univ Hosp Mainz, Oncol, Mainz, Germany
[7] Hosp Univ & Politecn La Fe, Med Oncol, Valencia, Spain
[8] Beth Israel Deaconess Med Ctr, Oncol, New York, NY 10003 USA
[9] Univ iPolitecn La Fe, Oncol, Valencia, Italy
[10] Celgene Corp, Oncol, Summit, NJ USA
[11] Rocky Mt Canc Ctr, Oncol Hematol, Denver, CO USA
来源：
ANNALS OF ONCOLOGY | 2017年 / 28卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1369P
引用
收藏
页数：2
相关论文
共 50 条
  • [31] The safety and efficacy of treatment with nab-paclitaxel and carboplatin for patients with advanced squamous non-small cell lung cancer with interstitial lung disease
    Fujita, Tetsuo
    Hiroishi, Takuma
    Yanagisawa, Asako
    Hayama, Noriko
    Amano, Hiroyuki
    Nakamura, Makoto
    Hirano, Satoshi
    Tabeta, Hiroshi
    Nakamura, Sukeyuki
    EUROPEAN RESPIRATORY JOURNAL, 2017, 50
  • [32] Interim safety results from the phase 2 ABOUND.PS2 study evaluating nab-paclitaxel (nab-P) plus carboplatin (C) followed by nab-P monotherapy in patients (pts) with NSCLC and an Eastern Cooperative Oncology Group (ECOG) performance status (PS) 2
    Gajra, A.
    Ali, H.
    Amiri, K. I.
    Karim, N. Abdel
    Matrana, M. R.
    Mulford, D.
    Ong, T. J.
    Sanford, A.
    Santos, E.
    Socinski, M.
    Spigel, D. R.
    Lilenbaum, R. C.
    ANNALS OF ONCOLOGY, 2016, 27
  • [33] Safety and Efficacy Results From ABOUND.70+: nab-Paclitaxel/Carboplatin in Elderly Patients With Advanced NSCLC
    Langer, Corey
    Goldman, Jonathan
    Amiri, Kathy
    Anderson, Eric
    DakhiLs, Shaker
    Haggstrom, Daniel
    Jotte, Robert
    Konduri, Kartik
    Modiano, Manuel
    Ong, Teng
    Sanford, Alexandra
    Smith, David
    Socoteanu, Matei
    Kim, Edward
    Weiss, Jared
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S916 - S917
  • [34] Dose escalation study of nab-paclitaxel followed by carboplatin as first line therapy in advanced non-small cell lung cancer (NSCLC).
    Hawkins, M. J.
    Georgy, M.
    Makhson, A.
    Cheporov, S.
    Sergey, O.
    Yablonsky, P.
    Bhar, P.
    Socinski, M.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 397S - 397S
  • [35] NAB-PACLITAXEL IN COMBINATION WITH CARBOPLATIN AS FIRST-LINE THERAPY IN DIABETIC PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC)
    Hirsh, Vera
    Owen, Scott
    Ko, Amy
    Renschler, Markus F.
    Socinski, Mark A.
    JOURNAL OF THORACIC ONCOLOGY, 2013, 8 : S584 - S584
  • [36] nab-Paclitaxel plus Carboplatin in Advanced Non-Small Cell Lung Cancer: Outcomes in Elderly Patients With Squamous Histology
    Gridelle, Cesare
    Chen, Tianlei
    Ko, Amy
    Ong, Teng Jin
    O'Brien, Mary
    Socinski, Mark
    Postmus, Pieter
    JOURNAL OF THORACIC ONCOLOGY, 2016, 11 (10) : S213 - S213
  • [37] Real-world outcomes of pembrolizumab plus carboplatin plus paclitaxel or nab-paclitaxel in non-small cell lung cancer (NSCLC).
    Tabah, Ashley
    Huggar, David
    Kish, Jonathan
    Bapat, Bela
    Liassou, Djibril
    Gajra, Ajeet
    Miller, Talia
    Copher, Ronda
    Patel, Manali, I
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [38] The Safety and Efficacy of Treatment with Nab-paclitaxel and Carboplatin for Patients with Advanced Squamous Non-small Cell Lung Cancer Concurrent with Idiopathic Interstitial Pneumonias
    Fujita, Tetsuo
    Hiroishi, Takuma
    Shikano, Kohei
    Yanagisawa, Asako
    Hayama, Noriko
    Amano, Hiroyuki
    Nakamura, Makoto
    Hirano, Satoshi
    Tabeta, Hiroshi
    Nakamura, Sukeyuki
    INTERNAL MEDICINE, 2018, 57 (13) : 1827 - 1832
  • [39] Phase 2 study of bevacizumab plus carboplatin/nab-paclitaxel followed by bevacizumab plus nab-paclitaxel for non-squamous non-small cell lung cancer with malignant pleural effusion
    Tamiya, Motohiro
    Tamiya, Akihiro
    Suzuki, Hidekazu
    Taniguchi, Yoshihiko
    Katayama, Kanako
    Minomo, Shojiro
    Nakao, Keiko
    Takeuchi, Naoko
    Matsuda, Yoshinobu
    Naito, Yujiro
    Shiroyama, Takayuki
    Okamoto, Norio
    Okishio, Kyoichi
    Kumagai, Toru
    Atagi, Shinji
    Imamura, Fumio
    Hirashima, Tomonori
    INVESTIGATIONAL NEW DRUGS, 2021, 39 (04) : 1106 - 1112
  • [40] nab-Paclitaxel/Carboplatin in Vulnerable Populations With Advanced Non-Small Cell Lung Cancer: Pooled Analysis
    Langer, Corey J.
    Gajra, Ajeet
    Gridelli, Cesare
    Konduri, Kartik
    Morgensztern, Daniel
    Spigel, David
    Talbot, Denis
    Thomas, Michael
    Weiss, Jared
    Pilot, Richard
    Bhore, Rafia
    Wolfsteiner, Marianne
    Ong, Teng Jin
    Socinski, Mark
    FRONTIERS IN ONCOLOGY, 2021, 10
12345